Activated HLA-DR+CD38+ Effector Th1/17 Cells Distinguish Crohn’s Disease-associated Perianal Fistulas from Cryptoglandular Fistulas

Journal Article (2024)
Authors

Laura F. Ouboter (Leiden University Medical Center)

Ciska Lindelauf (Leiden University Medical Center)

Qinyue Jiang (Leiden University Medical Center)

Mette Schreurs (Leiden University Medical Center)

T. Abdelaal (Cairo University, TU Delft - Pattern Recognition and Bioinformatics, Leiden University Medical Center)

Sietse J. Luk (Leiden University Medical Center)

Marieke C. Barnhoorn (Leiden University Medical Center)

Willem E. Hueting (Alrijne Ziekenhuis)

Andrea E. van der Meulen-de Jong (Leiden University Medical Center)

G.B. Cavadini

Research Group
Pattern Recognition and Bioinformatics
To reference this document use:
https://doi.org/10.1093/ibd/izae103
More Info
expand_more
Publication Year
2024
Language
English
Research Group
Pattern Recognition and Bioinformatics
Issue number
11
Volume number
30
Pages (from-to)
2146-2161
DOI:
https://doi.org/10.1093/ibd/izae103
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Background
Perianal fistulas are a debilitating complication of Crohn’s disease (CD). Due to unknown reasons, CD-associated fistulas are in general more difficult to treat than cryptoglandular fistulas (non-CD-associated). Understanding the immune cell landscape is a first step towards the development of more effective therapies for CD-associated fistulas. In this work, we characterized the composition and spatial localization of disease-associated immune cells in both types of perianal fistulas by high-dimensional analyses.

Methods
We applied single-cell mass cytometry (scMC), spectral flow cytometry (SFC), and imaging mass cytometry (IMC) to profile the immune compartment in CD-associated perianal fistulas and cryptoglandular fistulas. An exploratory cohort (CD fistula, n = 10; non-CD fistula, n = 5) was analyzed by scMC to unravel disease-associated immune cell types. SFC was performed on a second fistula cohort (CD, n = 10; non-CD, n = 11) to comprehensively phenotype disease-associated T helper (Th) cells. IMC was used on a third cohort (CD, n = 5) to investigate the spatial distribution/interaction of relevant immune cell subsets.

Results
Our analyses revealed that activated HLA-DR+CD38+ effector CD4+ T cells with a Th1/17 phenotype were significantly enriched in CD-associated compared with cryptoglandular fistulas. These cells, displaying features of proliferation, regulation, and differentiation, were also present in blood, and colocalized with other CD4+ T cells, CCR6+ B cells, and macrophages in the fistula tracts.

Conclusions
Overall, proliferating activated HLA-DR+CD38+ effector Th1/17 cells distinguish CD-associated from cryptoglandular perianal fistulas and are a promising biomarker in blood to discriminate between these 2 fistula types. Targeting HLA-DR and CD38-expressing CD4+ T cells may offer a potential new therapeutic strategy for CD-related fistulas.